Novo Nordisk Tops 3 Million Oral Wegovy Prescriptions, Reclaiming Share From Lilly
Updated
Updated · The Motley Fool · Jul 17
Novo Nordisk Tops 3 Million Oral Wegovy Prescriptions, Reclaiming Share From Lilly
2 articles · Updated · The Motley Fool · Jul 17
Summary
More than 3 million U.S. prescriptions for oral Wegovy were filled by June, making it one of the strongest drug launches on record by volume since its January debut.
About 80% of new scripts came from patients who had never used a GLP-1 drug, indicating the pill is expanding the obesity-treatment market rather than mainly shifting users from injectable Wegovy.
Roughly 89% of U.S. oral weight-loss prescriptions now go to oral Wegovy, helped by Wegovy's brand recognition, physician familiarity with semaglutide and stronger phase 3 efficacy than Lilly's Foundayo.
Eli Lilly still leads the broader obesity market with Zepbound, and Foundayo could narrow the oral gap because it has fewer dosing restrictions and may win label expansions in diabetes and other comorbidities.
The prescription surge shows Novo Nordisk can still counter Lilly in the fast-growing GLP-1 market, even as both companies rely on broader pipelines to sustain growth.
Oral Wegovy has higher efficacy, Foundayo has more convenience. Which will dominate the future of daily weight-loss medication?
Retatrutide promises surgical-level weight loss. Is it the future of obesity treatment or a dangerous, unregulated online experiment?
As Medicare begins covering obesity drugs, will this historic move solve the access crisis or create an unsustainable financial burden?
The $100 Billion Obesity Drug Race: Oral Wegovy’s Disruptive Launch, Market Expansion, and the Future of GLP-1 Therapies (2026–2028)
Overview
Since its launch in January 2026, Novo Nordisk’s oral Wegovy has rapidly expanded the obesity treatment market, driving strong investor confidence and boosting company shares. This success is especially important for Novo Nordisk, which has faced challenges with its next-generation metabolic drugs, including a less successful obesity shot compared to Lilly’s Zepbound. Meanwhile, Lilly is advancing its own innovative therapies, intensifying competition. Oral Wegovy’s appeal lies in attracting new patients who previously avoided injectables, helping Novo Nordisk maintain momentum despite setbacks and fierce rivalry in the evolving obesity drug landscape.